MBDB

MBDB (Methylbenzodioxolylbutanamine) is a psychoactive drug of the phenethylamine chemical class, which acts as entactogens, hallucinogens, and stimulants. It is known for its empathogenic effects and is related to the popular club drug MDMA (3,4-methylenedioxymethamphetamine), commonly known as ecstasy.

History

MBDB was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines I Have Known And Loved), Shulgin listed the dosage range as 180–210 mg. MBDB is the N-methylated form of MDEA (3,4-methylenedioxy-N-ethylamphetamine).

Pharmacology

Like other psychedelic drugs, MBDB primarily acts as a serotonin reuptake inhibitor, which means it effectively increases the levels of serotonin in the brain. This increase in serotonin levels can lead to feelings of happiness, euphoria, and increased empathy.

Effects

The effects of MBDB are similar to those of MDMA, but with less intensity. Users often report feelings of increased energy, euphoria, and empathy. However, unlike MDMA, MBDB does not typically produce visual or auditory hallucinations.

Legal Status

MBDB is a controlled substance in many countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act.

See Also

• MDMA
• MDEA
• Alexander Shulgin
• Psychedelic drug
• Phenethylamine